Cytokeratin-derived markersof lung cancer

References

• Minna JD, Higgins GA, Glatstein EJ.Cancer of the lung. In: Cancer Principles and Practice of Oncology (2nd Edition). De Vita VT, Jr., Hellman S, Rosemberg SA (Eds.), JB Lippincott, Philadelphia, USA, 507–597 (1985).
   Google Scholar
• Luna EJ, Hitt AL. Cytoskeleton-plasma membrane interactions. Science 258, 955–963 (1992).
   PubMed Web of Science ®Google Scholar
• •• An in-depth description of cytokeratin structure and function in prokaryotic cells.
   Google Scholar
• Lazarides E. Intermediate filaments as mechanical integrators of cellular space. Nature 283, 249–256 (1980).
   PubMed Web of Science ®Google Scholar
• Debus E, Moll R, Franke WW, Weber K, Osborn M. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am. Pathol 114, 121–130 (1984).
   Google Scholar
• Sundstrom BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. int. J. Biol. Markers 9(2), 102–108 (1994).
   Google Scholar
• Broers JL, Ramaekers PC, Rot MK eta]. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 48, 3221–3229 (1988).
   Google Scholar
• Stieber P, Dienemann H, Hasholzner U et al Comparison of CYFRA 21–1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int. j Biol. Markers 9, 82–88 (1994).
   Google Scholar
• Ferrigno D, Buccheri G, Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eric Respir. 7(1), 186–197 (1994).
   PubMed Web of Science ®Google Scholar
• • An overview of the biology and clinical use of lung tumor markers, still very up-to-date.
   Google Scholar
• Nildinski J, Furman M. Clinical tumour markers in lung cancer. Eur. j Cancer Prey. 4(2), 129–138 (1995).
   PubMed Web of Science ®Google Scholar
• Ferrigno D, Buccheri G. Clinical applications of serum markers for lung cancer. Respir. Med. 89, 587–597 (1995).
   PubMed Web of Science ®Google Scholar
• Buccheri G. Tumor markers: clinical meaning and use. In: Lung Tumors (1st Edition). Brambilla C, Brambilla E (Eds.), Marcel Dekker, New York, USA, 435–452 (1999).
   Google Scholar
• Bjorldund B. Serological analysis of human cancer antigen. Proc. VI Int.CongressNlicrobiol Rome, Italy, 344 (1953).
   Google Scholar
• Bjorldund B, Bjorldund V. Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique: presence of an insoluble, heat-labile tumor antigen. Int. Arch. Allergy10,153–184 (1957).
   Web of Science ®Google Scholar
• Bjorldund B, Lundblad G, Bjorldund V. Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique: II. Nature of tumor antigen. Int. Airh. Allergy12, 241–261 (1958).
   Google Scholar
• Bjorklund B, Bjorklund V, Wiklund B eta]. A human tissue polypeptide related to cancer and placenta: I. preparation and properties, II. Assay technique, III. Clinical studies of 1483 individuals with cancer and other conditions. In: Immunological Techniques for Detection of Cancer. Bjorklund B (Ed.), Bonniers, Stockholm, Sweden, 133–187 (1973).
   Google Scholar
• Luning B, Nilsson U. Sequence homology between tissue polypeptide antigen (TPA) and intermediate filament (IF) proteins. Acta Chem. Scand B 37,731–733 (1983).
   PubMedGoogle Scholar
• Weber K, Osborn M, Moll R, Wiklund B, Luning B. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8,18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMI30 J. 3(11), 2707–2714 (1984).
   Google Scholar
• Pujol JL, Grenier J, Parrat E eta]. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21–1 and TPS. Am. Respir. Grit Care Med 154(3 Pt 1), 725–733 (1996).
   Google Scholar
• Pujol JL, Cooper EH, Grenier J eta]. Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer. Eur. j Cancer 30A(12), 1768–1774 (1994).
   Google Scholar
• Bodenmuller H, Banauch D, Ofenloch B, Jaworek D, Dessauer A. Technical evaluation of a new automated tumor marker assay: the Enzymun-Test CYFRA 21–1. In: Tumor-Associatecl Antigens, Oncogens, Receptors, Cytochines in Tumor Diagnosis and Therapy at the Beginning of the 90th. KLapdor R (Ed.), Springer Verlag, Berlin, Germany, 137–138 (1992).
   Google Scholar
• Buccheri G. Circulating biomarkers for lung cancer. Ann. Ital. Chir. 70(6), 831–838 (1999).
   Google Scholar
• Buccheri G, Ferrigno D. The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: diagnostic yield and comparison with conventional staging methods. Chest 107,471–476 (1995).
   PubMed Web of Science ®Google Scholar
• • A study showing how TPA can be used to predict surgical resectability.
   Google Scholar
• Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur. Respir. 7(7), 1350–1364 (1994).
   PubMed Web of Science ®Google Scholar
• • Evidence on hundreds of known prognostic factors is reviewed in a semiquantitative way.
   Google Scholar
• Gold P, Freedman SO. Demonstration of tumor-specific antigenin in human colonic carcinomata by immunological tolerance and absorption techniques. I Exp. Med. 121,439–462 (1965).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Powels TJ. Tumour markers in the management of human cancer. In: Topical Reviews in Radiotherapy and Oncology Deeley TJ (Ed.), Wright PGS, Bristol, USA, 39 (1982).
   Google Scholar
• Buccheri G, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola E Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 57, 2389–2396 (1986).
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma: superiority of tissue polyptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer60, 42–50 (1987).
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D. Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer. Chest 93,565–569 (1988).
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D. Prognostic value of the tissue polyptide antigen in lung cancer. Chest101, 1287–1292 (1992).
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D, Vola Carcinoembryonic antigen (CEA), tissue polyptide antigen (TPA) and other prognostic indicators in the squamous cell carcinoma of the lung. Lung- Cancer10,21–33 (1993).
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D. Monitoring lung cancer with tissue polyptide antigen: an ancillary, profitable serum test to evaluate treatment response and post-treatment disease status. Lung- Cancer 13,155–168 (1995).
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D. Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase. Lung- Cancer30(1), 37–49 (2000).
   Google Scholar
• Mizushima Y, Hirata H, Izumi S etal Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay. Oncology47, 43–48 (1990).
   PubMed Web of Science ®Google Scholar
• Gronowitz JS, Bergstrom R, Nou E eta]. Clinical and serologic markers of stage and prognosis in small cell lung cancer. Cancer 66,722–732 (1990).
   Google Scholar
• Van der Gaast A, Van Putten WL, Oosterom R, Cozijnsen M, Hoekstra R, Splinter TA. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neurone specific enolase in patients with small cell lung cancer. BE Cancer64, 369–372 (1991).
   Web of Science ®Google Scholar
• Van der Gaast A, Kok TC, Kho GS, Blijenberg BG, Splinter TAW Disease monitoring by the tumour markers Cyfra 21.1 and TPA in patients with non-small cell lung cancer. Eur j Cancer31A, 1790–1793 (1995).
   Google Scholar
• Rastel D, Ramaioli A, Cornillie F, Thirion B. CYFRA 21–1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. Eur. j Cancer 30A, 601–606 (1994).
   Google Scholar
• Correale M, Arnberg H, Blockx P et al Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Int. j Biol. Markets 9, 231–238 (1994).
   PubMedGoogle Scholar
• Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results. Brj Cancer72, 170–173 (1995).
   PubMed Web of Science ®Google Scholar
• Trevisani L, Putinati S, Sartori S, Abbasciano V, Bagni B. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Chest 109,104–108 (1996).
   Google Scholar
• Kashiwabara K, Nakamura H, Kiguchi T et al Correlation between serum cytokeratin 19 fragments and tissue polypeptide antigen levels in patients with non-small cell lung cancer. Clin. Chim. Acta 266 (2), 149–155 (1997).
   Google Scholar
• Ebert W, Hoppe M, Muley T, Drings Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21–1, TPA- TP CEA and NSE. Anticancer Res. 17(4B), 2875–2878 (1997).
   Google Scholar
• Bates J, Rutherford R, Divilly M etal Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir. 10(11), 2535–2538 (1997).
   Google Scholar
• Foa P, Fornier M, Miceli R etal Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non- small cell lung cancer. Anticancer Res. 19(4C), 3613–3618 (1999).
   Google Scholar
• Watine J, Charet JC. [Primary small-cell bronchial cancer: value of serum tumor markers in the prognostic evaluation]. Pmsse Med. 28(28), 1541–1546 (1999).
   Google Scholar
• Prados C, Alvarez-Sala R, Gomez dT eta]. An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients. Jpn. Clin. Oncol 30(5), 215–220 (2000).
   Google Scholar
• Rapellino M, Pecchio F, Baldi S, Scappaticci E, Cavallo A. Clinical utility of tissue polypeptide antigen determination in lung cancer management. Anticancer Res. 15,1065–1070 (1995).
   Google Scholar
• Ferrigno D, Buccheri G, Rendine S. The prognostic value of CEA and TPA in the initial evaluation of lung cancer: results of a multivariate analysis of 312 patients. In: Lung Cancer: Advanced Concepts and Present Status. Motta G (Ed.), IASLG, Genova, Italy, 179–188 (1989).
   Google Scholar
• Marino P, Buccheri G, Preatoni A, Ferrigno D, Luporini AC, Pravettoni G. Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumors. Int. Biol. Markers 7,65–67 (1992).
   PubMedGoogle Scholar
• Giovanella L, Ceriani L, Bandera M, Rimoldi R, Beghe B, Roncari G. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non-small cell lung cancer evaluation. Q. J. Nucl. Med. 39(4), 285–289 (1995).
   Google Scholar
• Giovanella L, Ceriani L, Bandera M, Beghe B, Roncari G. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. Int. J. Biol. Markeis10(3), 156–160 (1995).
   Google Scholar
• Van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Hop WC, Splinter TA. Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer. Eur I Cancer30 A(12), 1783–1786 (1994).
   Google Scholar
• Ray P, Quantin X, Grenier J, Pujol JL. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect. Prey. 22(4), 293–304 (1998).
   Google Scholar
• Nisman B, Lafair J, Heching N etal Evaluation of tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen in nonsmall cell lung carcinoma — does the combined use of cytokeratin markers give any additional information. Cancer 82,1850–1859 (1998).
   PubMed Web of Science ®Google Scholar
• Boher JM, Pujol JL, Grenier J, Daures JP. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21–1 and TPS levels on prognosis. Br. J. Cancer 79(9–10), 1419–1427 (1999).
   Google Scholar
• Nisman B, Amir G, Lafair J eta]. Prognostic value of CYFRA 21–1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res. 19(4C), 3549–3552 (1999).
   Google Scholar
• Ebert W, Leichtweis B, Schapohler B, Muley TH. The new tumor marker CYFRA 21–1 is superior to SCC antigen and CEA in the primary diagnosis of lung cancer. Tumor Diagn. Thec 3,91–99 (1993).
   Google Scholar
• Ebert W, Muley T CYFRA 21–1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res. 19 (4A), 2669–2672 (1999).
   Google Scholar
• Stieber P, Hasholzner U, Bodenmüller H et al CYFRA 21-1: A new marker in lung cancer. Cancer 72,707–713 (1993).
   PubMed Web of Science ®Google Scholar
• Stieber P, Zimmermann A, Reinmiedl J, Muller C, Hoffmann H, Dienemann H. CYFRA 21–1 in the early diagnosis of recurrent disease in non-small cell lung carcinomas (NSCLC). Anticancer Res. 19(4A), 2665–2668 (1999).
   Google Scholar
• Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53, 61–66 (1993).
   PubMed Web of Science ®Google Scholar
• Pujol J, Boher J, Grenier J, Quantin X. Cyfra 21–1, neurone specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung-Cancer31(2–3), 221–231 (2001).
   Google Scholar
• Sugama Y, Kitamura S, Kawai T eta]. Clinical usefulness of CYFRA assay in diagnosing lung cancer: Measurement of serum cytokeratin fragment. Jpn. 1 Cancer Res. 85,1178-1184 (1994).
   Google Scholar
• Van der Gaast A, Schoenmakers CIII I, Kok TC, Blijenberg BG, Cornillie F, Splinter TAW Evaluation of a new tumour marker in patients with non-small cell lung cancer: CIFRA 21–1. Br. Cancer69, 525–528 (1994).
   Google Scholar
• Nildinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J. Diagnostic and prognostic value of the new tumour marker CIFRA 21–1 in patients with squamous cell lung cancer. Eur. Resp. J. 8,291-294 (1995).
   Google Scholar
• Nildinski J, Furman M, Burzykowski T et al Preoperative CYFRA 21–1 level as a prognostic indicator in resected primary squamous cell lung cancer. Br. J. Cancer 74, 956–960 (1996).
   Google Scholar
• Nildinski J, Burzykowski T, Niklinska Wet al Preoperative CYFRA 21–1 level as a prognostic indicator in resected non-small cell lung cancer. Eur. Rasp. 12,1424-1428 (1998).
   Google Scholar
• Takada M, Masuda N, Matsuura E et al Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21–1 enzyme immunoassay. Br. J. Cancer71, 160–165 (1995).
   Google Scholar
• Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S. Assessment of serum CYFRA 21-1 in lung cancer. Cancer 77,1274–1277 (1996).
   PubMed Web of Science ®Google Scholar
• Lai RS, Hsu HK, Lu JY, Ger LP, Lai NS. CYFRA 21–1 enzyme-linked immunosorbent assay — evaluation as a tumor marker in non-small cell lung cancer. Chest 109,995–1000 (1996).
   Google Scholar
• Maeda Y, Segawa Y, Takigawa N, Takata I, Fujimoto N. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. InternMed 35,764–771 (1996).
   Google Scholar
• Huang MS, Jong SB, Tsai MS eta]. Comparison of cytokeratin fragment 19 (CYFRA 21–1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir. Med. 91(3), 135–142 (1997).
   Google Scholar
• Kashiwabara K, Nakamura H, Esaki T Serum cytokeratin 19 fragment levels in non-small cell lung cancer patients according to T factor in the TNM classification. Clip. Chim. Acta 288(1–2), 153–159 (1999).
   Google Scholar
• Bréchot JM, Chevret S, Nataf J et al Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur Cancer 33,385–391 (1997).
   PubMed Web of Science ®Google Scholar
• Hirashima T, Takada M, Komiya T eta]. Prognostic significance of CYFRA 21–1 in non-small cell lung cancer. Anticancer Res. 18(6B), 4713–4716 (1998).
   Google Scholar
• Seemann MD, Beinert T, Furst H, Fink U. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21–1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung- Cancer 26(3), 149–155 (1999).
   Google Scholar
• Huang MS, Jong SB, Lin MS eta]. Cytokeratin fragment 19 (CYFRA 21–1) as a tumor marker in non-small cell lung cancer. Kao. Iliung. I Hsueh. Ko. Hsueh. Tsa. Chili. 12,62-68 (1996).
   Google Scholar
• Dienemann H, Stieber P, Zimmermann A, Hoffmann H, Muller C, Banauch D. Tumor-marker CYFRA 21–1 in non-small cell lung cancer (NSCLC): role for detection of recurrence. Lung Cancer 11 (supp1.1), 46 (1994).
   Google Scholar
• American Thoracic Society, European Respiratory Society. Pretreatment evaluation of non-small cell lung cancer. Am. .1. Respir. Grit. Cam Med. 156,320-332 (1998).
   Google Scholar
• •• The currently adopted clinical guidelines by the two medical societies..
   Google Scholar